288 related articles for article (PubMed ID: 33231381)
1. Investigation of drugs affecting hypertension in bevacizumab-treated patients and examination of the impact on the therapeutic effect.
Yagi K; Mitstui M; Zamami Y; Niimura T; Izawa-Ishizawa Y; Goda M; Chuma M; Fukunaga K; Shibata T; Ishida S; Sakurada T; Okada N; Hamano H; Horinouchi Y; Ikeda Y; Yanagawa H; Ishizawa K
Cancer Med; 2021 Jan; 10(1):164-172. PubMed ID: 33231381
[TBL] [Abstract][Full Text] [Related]
2. Treatment of bevacizumab-induced hypertension by amlodipine.
Mir O; Coriat R; Ropert S; Cabanes L; Blanchet B; Camps S; Billemont B; Knebelmann B; Goldwasser F
Invest New Drugs; 2012 Apr; 30(2):702-7. PubMed ID: 20878444
[TBL] [Abstract][Full Text] [Related]
3. Risk factors increasing blood pressure in Japanese colorectal cancer patients treated with bevacizumab.
Nishihara M; Morikawa N; Yokoyama S; Nishikura K; Yasuhara M; Matsuo H
Pharmazie; 2018 Nov; 73(11):671-675. PubMed ID: 30396388
[TBL] [Abstract][Full Text] [Related]
4. Retrospective cohort study on the safety and efficacy of bevacizumab with chemotherapy for metastatic colorectal cancer patients: the HGCSG0801 study.
Sogabe S; Komatsu Y; Yuki S; Kusumi T; Hatanaka K; Nakamura M; Kato T; Miyagishima T; Hosokawa A; Iwanaga I; Sakata Y; Asaka M
Jpn J Clin Oncol; 2011 Apr; 41(4):490-7. PubMed ID: 21303790
[TBL] [Abstract][Full Text] [Related]
5. Retrospective analysis of bevacizumab-induced hypertension and clinical outcome in patients with colorectal cancer and lung cancer.
Nakaya A; Kurata T; Yokoi T; Iwamoto S; Torii Y; Katashiba Y; Ogata M; Hamada M; Kon M; Nomura S
Cancer Med; 2016 Jul; 5(7):1381-7. PubMed ID: 27109438
[TBL] [Abstract][Full Text] [Related]
6. Decreased peritherapeutic VEGF expression could be a predictor of responsiveness to first-line FOLFIRI plus bevacizumab in mCRC patients.
Tsai HL; Lin CH; Huang CW; Yang IP; Yeh YS; Hsu WH; Wu JY; Kuo CH; Tseng FY; Wang JY
Int J Clin Exp Pathol; 2015; 8(2):1900-10. PubMed ID: 25973082
[TBL] [Abstract][Full Text] [Related]
7. Bevacizumab-induced hypertension: pathogenesis and management.
Syrigos KN; Karapanagiotou E; Boura P; Manegold C; Harrington K
BioDrugs; 2011 Jun; 25(3):159-69. PubMed ID: 21627340
[TBL] [Abstract][Full Text] [Related]
8. Early hypertension and neutropenia are predictors of treatment efficacy in metastatic colorectal cancer patients administered FOLFIRI and vascular endothelial growth factor inhibitors as second-line chemotherapy.
Osumi H; Shinozaki E; Ooki A; Wakatsuki T; Kamiimabeppu D; Sato T; Nakayama I; Ogura M; Takahari D; Chin K; Yamaguchi K
Cancer Med; 2021 Jan; 10(2):615-625. PubMed ID: 33347731
[TBL] [Abstract][Full Text] [Related]
9. Effects of vonoprazan and proton pump inhibitors on the efficacy of bevacizumab: a multicentre retrospective study.
Yagi K; Maruo A; Ishida S; Aizawa F; Ushio S; Sakaguchi S; Kajizono M; Niimura T; Goda M; Hamano H; Izawa-Ishizawa Y; Zamami Y; Ishizawa K
Clin Exp Med; 2023 Oct; 23(6):2799-2804. PubMed ID: 36738305
[TBL] [Abstract][Full Text] [Related]
10. Bevacizumab safety in Japanese patients with colorectal cancer.
Hatake K; Doi T; Uetake H; Takahashi Y; Ishihara Y; Shirao K
Jpn J Clin Oncol; 2016 Mar; 46(3):234-40. PubMed ID: 26774113
[TBL] [Abstract][Full Text] [Related]
11. Severe cutaneous adverse reactions associated with immune checkpoint inhibitors therapy and anti-VEGF combination therapy: a real-world study of the FDA adverse event reporting system.
Li C; Li Z; Sun Q; Xiang Y; Liu A
Expert Opin Drug Saf; 2024 Jun; 23(6):777-784. PubMed ID: 37622438
[TBL] [Abstract][Full Text] [Related]
12. Association between bevacizumab-related hypertension and vascular endothelial growth factor (VEGF) gene polymorphisms in Japanese patients with metastatic colorectal cancer.
Morita S; Uehara K; Nakayama G; Shibata T; Oguri T; Inada-Inoue M; Shimokata T; Sugishita M; Mitsuma A; Ando Y
Cancer Chemother Pharmacol; 2013 Feb; 71(2):405-11. PubMed ID: 23161411
[TBL] [Abstract][Full Text] [Related]
13. Modified XELIRI (capecitabine plus irinotecan) versus FOLFIRI (leucovorin, fluorouracil, and irinotecan), both either with or without bevacizumab, as second-line therapy for metastatic colorectal cancer (AXEPT): a multicentre, open-label, randomised, non-inferiority, phase 3 trial.
Xu RH; Muro K; Morita S; Iwasa S; Han SW; Wang W; Kotaka M; Nakamura M; Ahn JB; Deng YH; Kato T; Cho SH; Ba Y; Matsuoka H; Lee KW; Zhang T; Yamada Y; Sakamoto J; Park YS; Kim TW
Lancet Oncol; 2018 May; 19(5):660-671. PubMed ID: 29555258
[TBL] [Abstract][Full Text] [Related]
14. [Analysis of hypertension in advanced, recurrent colorectal cancer patients treated with first-line bevacizumab].
Yamamura K; Ishigure K
Gan To Kagaku Ryoho; 2011 Jan; 38(1):85-8. PubMed ID: 21368463
[TBL] [Abstract][Full Text] [Related]
15. Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study.
Lee MS; Ryoo BY; Hsu CH; Numata K; Stein S; Verret W; Hack SP; Spahn J; Liu B; Abdullah H; Wang Y; He AR; Lee KH;
Lancet Oncol; 2020 Jun; 21(6):808-820. PubMed ID: 32502443
[TBL] [Abstract][Full Text] [Related]
16. Adverse effects of bevacizumab in metastatic colorectal cancer : a case report and literature review.
Willems E; Gerne L; George C; D'Hondt M
Acta Gastroenterol Belg; 2019; 82(2):322-325. PubMed ID: 31314196
[TBL] [Abstract][Full Text] [Related]
17. Novel adverse events of bevacizumab in the US FDA adverse event reporting system database: a disproportionality analysis.
Shamloo BK; Chhabra P; Freedman AN; Potosky A; Malin J; Weiss Smith S
Drug Saf; 2012 Jun; 35(6):507-18. PubMed ID: 22612854
[TBL] [Abstract][Full Text] [Related]
18. Association of hypertension and treatment outcomes in advanced stage non-small cell lung cancer patients treated with bevacizumab or non-bevacizumab containing regimens.
Yan LZ; Dressler EV; Adams VR
J Oncol Pharm Pract; 2018 Apr; 24(3):209-217. PubMed ID: 29284349
[TBL] [Abstract][Full Text] [Related]
19. Bevacizumab plus XELOX as first-line treatment of metastatic colorectal cancer: The OBELIX study.
Antonuzzo L; Giommoni E; Pastorelli D; Latiano T; Pavese I; Azzarello D; Aieta M; Pastina I; Di Fabio F; Bertolini A; Corsi DC; Mogavero S; Angelini V; Pazzagli M; Di Costanzo F
World J Gastroenterol; 2015 Jun; 21(23):7281-8. PubMed ID: 26109816
[TBL] [Abstract][Full Text] [Related]
20. Management of hypertension in angiogenesis inhibitor-treated patients.
Izzedine H; Ederhy S; Goldwasser F; Soria JC; Milano G; Cohen A; Khayat D; Spano JP
Ann Oncol; 2009 May; 20(5):807-15. PubMed ID: 19150949
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
